Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) - Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Zai Lab in a research note issued to investors on Tuesday, July 1st. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.95) per share for the year, down from their previous forecast of ($0.94). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab's FY2026 earnings at $0.30 EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The business had revenue of $106.49 million for the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%.

A number of other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, March 13th. Leerink Partners set a $75.00 target price on Zai Lab and gave the stock an "outperform" rating in a research note on Monday, June 30th. Finally, Wall Street Zen cut Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $54.28.

Zai Lab Stock Up 2.6%

Shares of ZLAB stock traded up $0.94 on Thursday, reaching $36.43. The stock had a trading volume of 581,960 shares, compared to its average volume of 914,335. Zai Lab has a 12 month low of $16.01 and a 12 month high of $44.34. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of -14.63 and a beta of 0.99. The firm's 50-day moving average is $33.80 and its two-hundred day moving average is $31.45.

Insider Buying and Selling at Zai Lab

In other news, Director William Lis sold 13,814 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.67, for a total value of $492,745.38. Following the transaction, the director owned 35,106 shares of the company's stock, valued at approximately $1,252,231.02. This represents a 28.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $28.57, for a total value of $1,428,500.00. Following the sale, the chief executive officer directly owned 479,851 shares of the company's stock, valued at approximately $13,709,343.07. The trade was a 9.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 160,155 shares of company stock valued at $4,959,535 in the last three months. 4.96% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zai Lab

A number of institutional investors have recently modified their holdings of ZLAB. Acadian Asset Management LLC acquired a new stake in Zai Lab in the 1st quarter worth about $1,073,000. MPM Bioimpact LLC increased its holdings in shares of Zai Lab by 4.2% during the first quarter. MPM Bioimpact LLC now owns 833,659 shares of the company's stock worth $30,128,000 after purchasing an additional 33,659 shares during the period. Frazier Life Sciences Management L.P. acquired a new stake in shares of Zai Lab in the first quarter valued at approximately $12,649,000. Cubist Systematic Strategies LLC boosted its stake in shares of Zai Lab by 29.0% in the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company's stock valued at $3,384,000 after buying an additional 21,026 shares during the period. Finally, Royal Bank of Canada grew its position in Zai Lab by 214.3% during the first quarter. Royal Bank of Canada now owns 13,771 shares of the company's stock worth $498,000 after buying an additional 9,390 shares in the last quarter. Institutional investors own 41.65% of the company's stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.